FRA:HPR (Ireland)  
Horizon Therapeutics PLC logo

Horizon Therapeutics PLC

€ 101.34 (-0.37%) Jan 30
P/E:
45.10
P/B:
5.00
Market Cap:
€ 23.12B ($ 25.03B)
Enterprise V:
€ 23.50B ($ 25.44B)
Volume:
-
Avg Vol (2M):
93.00
Also Trade In:
Volume:
-
Market Cap €:
23.12B
Market Cap $:
25.03B
PE Ratio:
45.10
Avg Vol (2-Month):
93.00
Enterprise Value €:
23.50B
Enterprise Value $:
25.44B
PB Ratio:
5.00

Business Description

Description
Horizon Therapeutics PLC is a specialty and generic drug manufacturing company. The company is focused on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company has two reportable segments: orphan and inflammation. Orphan segment consists of medicines such as TEPEZZA, KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, UPLIZNA, BUPHENYL, and QUINSAIR. Inflammation segment consists of PENNSAID 2%, DUEXIS, RAYOS, and VIMOVO. It generates the vast majority of its revenue from the United States.
Name Current Vs Industry Vs History
Cash-To-Debt 0.84
Equity-to-Asset 0.56
Debt-to-Equity 0.51
Debt-to-EBITDA 2.42
Interest Coverage 8.4
Piotroski F-Score 6/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 4.86
Distress
Grey
Safe
Beneish M-Score -2.97
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 24.34
9-Day RSI 35.45
14-Day RSI 46.16
6-1 Month Momentum % 28.66
12-1 Month Momentum % 33.15

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.96
Quick Ratio 3.74
Cash Ratio 2.5
Days Inventory 85.9
Days Sales Outstanding 67.3
Days Payable 15.74

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -10.4